BiotechTube

CT-P17 SC AI (adalimumab)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rheumatoid Arthritis

Conditions

Rheumatoid Arthritis

Trial Timeline

Sep 9, 2019 → Apr 24, 2020

NCT ID
NCT04171414

About CT-P17 SC AI (adalimumab)

CT-P17 SC AI (adalimumab) is a phase 3 stage product being developed by Celltrion for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04171414. Target conditions include Rheumatoid Arthritis.

What happened to similar drugs?

20 of 20 similar drugs in Rheumatoid Arthritis were approved

Approved (20) Terminated (0) Active (0)
✅Baricitinib + TNF InhibitorEli LillyApproved
✅TacrolimusAstellas PharmaApproved
✅tacrolimus + methotrexate + adalimumab + tocilizumab + abataceptAstellas PharmaApproved
✅tacrolimus + placeboAstellas PharmaApproved
✅TacrolimusAstellas PharmaApproved
✅TacrolimusAstellas PharmaApproved
✅Methotrexate (MTX)EisaiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04171414Phase 3Completed

Competing Products

20 competing products in Rheumatoid Arthritis

See all competitors
ProductCompanyStageHype Score
DRL_RI + Rituxan + MabTheraDr. Reddy's LaboratoriesPhase 1/2
29
Experimental: Arm A: DRL_RI + Arm B: Rituxan®/Mabthera®Dr. Reddy's LaboratoriesPhase 3
37
Test Product + Reference product + Reference Medicinal ProductDr. Reddy's LaboratoriesPhase 1
22
Tocilizumab Prefilled SyringeDr. Reddy's LaboratoriesPhase 1
26
TilmanoceptNavidea BiopharmaceuticalsPhase 1
11
Tc99m tilmanoceptNavidea BiopharmaceuticalsPhase 2
25
KPL-404 + PlaceboKiniksa PharmaceuticalsPhase 2
29
Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic AcidEli LillyPhase 3
40
LY2127399Eli LillyPhase 3
32
Baricitinib + TNF InhibitorEli LillyApproved
43
Remsima IV + Remsima SCCelltrionPre-clinical
33
CT-P13 + RemicadeCelltrionPhase 3
40
CT-P47 + EU-approved RoActemraCelltrionPhase 3
40
InfliximabCelltrionPhase 3
40
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
Rituximab, MTX, folic acidCelltrionPhase 1
29
CT-P10 + Rituxan + MabTheraCelltrionPhase 3
40
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)CelltrionPhase 3
36
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 3
40
rituximabCelltrionPhase 1
29